Related Experiment Video
Updated: Aug 13, 2026
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
Controlled trial of furosemide therapy in infants with chronic lung disease
Insights
Furosemide significantly improves lung function in infants with chronic lung disease (CLD). This therapy allows for earlier weaning from ventilators and oxygen support, enhancing recovery.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Pharmacology
Background:
- Chronic lung disease (CLD) poses significant challenges in infant care, often requiring prolonged respiratory support.
- Infants with CLD exhibit impaired lung function and increased oxygen dependency.
- Effective therapeutic strategies for CLD in neonates are crucial for improving outcomes.
Purpose of the Study:
- To evaluate the efficacy of furosemide in improving lung function in infants diagnosed with CLD.
- To assess the impact of furosemide on clinical status, respiratory support needs, and pulmonary mechanics.
- To compare the effects of furosemide with placebo in a double-blind controlled trial setting.
Main Methods:
- A double-blind, placebo-controlled trial involving 17 infants with confirmed CLD.
- Administration of either furosemide (intravenous or oral) or placebo for a specified duration.
- Measurement of pulmonary function parameters, including ventilator and oxygen requirements, before and during treatment.
Main Results:
- Significant clinical improvement observed in 6 of 7 infants receiving furosemide, compared to 2 of 10 in the placebo group (P < 0.002).
- Furosemide treatment led to decreased ventilator and oxygen needs (P < 0.003), increased ventilation and dynamic compliance, and reduced venous admixture (P < 0.05).
- No significant changes in pulmonary function or clinical status were noted in the placebo group.
Conclusions:
- Furosemide demonstrates significant efficacy in improving lung function in infants with CLD.
- Therapy with furosemide facilitates earlier discontinuation of mechanical ventilation and supplemental oxygen.
- Furosemide represents a valuable therapeutic option for managing infants suffering from chronic lung disease.
Abstract:
To study the effects of furosemide therapy in infants with chronic lung disease (CLD), a double-blind controlled trial was designed. Seventeen infants with evidence of CLD (oxygen requirements greater than 30% at greater than 3 weeks of age and chest radiographic findings consistent with CLD) were studied. Pulmonary function was measured immediately before, and after 48 hours and 7 days of treatment with furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally) or placebo. Clinical status improved in six of seven infants who received furosemide and in two of 10 infants who received placebo (P less than 0.002). In the furosemide group, ventilator and oxygen requirements decreased (P less than 0.003); minute ventilation, alveolar ventilation, and dynamic compliance increased; and venous admixture decreased (P less than 0.05). There were no significant changes in the placebo group. Our findings suggest that furosemide significantly improves lung function during therapy in infants with CLD and allows earlier weaning from ventilatory support and supplemental oxygen.
Related Concept Videos
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:20Acute Kidney Injury V: Interprofessional Care